Physician profile
Michael John Leser
NPI 1568697258
$13,304.51
in general payments reported to CMS, 2019-2025
56 companies · $2,691 in 2025
The $2,691 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,392 · 2020: $812 · 2021: $1,756 · 2022: $1,162 · 2023: $2,353 · 2024: $3,137 · 2025: $2,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,127 · Education: $54.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,127.20 |
| Education | $54.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,289.45 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,487.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,465.72 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $1,093.83 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,052.92 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $631.34 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $434.68 | 2019-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $320.37 | 2019-2025 | Spravato |
| Sanofi-Aventis U.S. LLC | $319.76 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $311.01 | 2021-2025 | Rexulti |
| Exact Sciences Corporation | $307.57 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $244.07 | 2019-2023 | Trintellix |
| Astellas Pharma US INC | $221.95 | 2019-2025 | Veozah |
| Amarin Pharma, INC. | $199.80 | 2019-2022 | |
| Alcon Vision LLC | $199.09 | 2023 | Clareon |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Leser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.